Newish Biotech registers second HPV-16 cervical HSIL vaccine trial
The Phase 2 study of NWRD09 joins the sponsor's own NWRD08 program and a Shanghai Mianyi rival in a cervical HSIL field where no mechanism has yet cleared a regulatory bar.
Executive Summary
- Newish Biotech has registered a Phase 2 trial of a second cervical HSIL candidate, built as a randomized, placebo-controlled study rather than an open-label signal-seeking design.
- The company already sponsors a separate Phase 2 trial for a related cervical HSIL therapy, so this filing adds a second internal program targeting the same patient population and endpoint structure.
- Cervical HSIL treatment trials span several distinct modalities from different sponsors, none of which has yet produced a resolved regulatory outcome, leaving open which approach the field will validate first.
- The trial has not yet begun enrolling, so its lesion-regression and HPV-clearance data will not be available until well after the study's mid-2027 primary completion target.
The trial
The study, filed as NCT07712692, will test NWRD09 against placebo in a randomized, quadruple-masked design intended to enroll 156 adult women with histopathologically confirmed cervical HSIL and HPV-16 genotyping-positive infection. The primary endpoint measures the proportion of participants whose cervical lesions regress from CIN2/3 to non-HSIL, either LSIL/CIN1 or no lesion, at week 24. Secondary measures track full lesion clearance, virologic clearance of HPV-16, cellular and humoral immune responses through week 48, and safety through week 64, including serious adverse events and treatment-related discontinuations. The trial is listed as not yet recruiting, with a planned start of August 1, 2026, and a primary completion date of June 30, 2027, across 15 sites in China. NCT07712692+1Evaluation of NWRD09 for HPV-16 Related Cervical HSILNCT07712692Newish Biotech Registers Phase 2 Trial of NWRD09 for Cervical HSIL (HPV-16)Jul 17, 2026
Design and stake
The design, randomized and placebo-controlled with 156 planned participants, is built to produce a controlled histopathological regression readout rather than a hypothesis-generating open-label signal. That distinguishes the trial's information value from a small safety cohort: if it enrolls and completes on the guided timeline, week-24 regression and HPV-16 clearance data will be interpretable against a placebo arm rather than a historical or single-arm comparison. Newish+1Newish Biotech Registers Phase 2 Trial of NWRD09 for Cervical HSIL (HPV-16)Jul 17, 2026Evaluation of NWRD09 for HPV-16 Related Cervical HSILNCT07712692
The internal overlap
Newish Biotech already sponsors a separate Phase 2 cervical HSIL trial for a related candidate, NWRD08, also filed against the same indication. The company's broader pipeline includes six trials in total, four recruiting and two not yet recruiting, of which NWRD09 is one. Running two Phase 2 programs in the same disease population is not itself a red flag, but it does mean the sponsor is testing more than one internal approach to the same clinical question before either has posted data.
The competitive field
Other sponsors are also active against HPV-16-related lesions with different mechanisms: Shanghai Mianyi Biopharmaceutical's BBM-C101 is a gene therapy targeting HPV16 E6 in a Phase 1/2 cervical HSIL trial, and CSPC Megalith Biopharmaceutical's SYS6026 targets HPV16 in a not-yet-recruiting Phase 2 study. None of these programs share NWRD09's target or mechanism class, since NWRD09's target is not resolved in the available record, so the comparison rests on indication and modality rather than mechanism. Across the broader HPV-related trial landscape, six of eight active studies are based in China, with only two other candidates, Ferring's nadofaragene firadenovec and Daiichi Sankyo's patritumab deruxtecan, in different indications, appearing as contextual rather than direct comparators.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.